CD81 and acute lymphoblastic leukemia: The other two B-cell tumors presented with a CD45+lo, CD19+, CD20−, CD22+, CD10−, CD38+, CD58+, CD81+, CD9+, SmIg−, CyIgμ− phenotype compatible with B-cell precursor acute lymphoblastic lymphoma (BCP-ALL) by both MFC and histopathology.